FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer

Kylie A McLaughlin1, Zsuzsanna Nemeth1, Conor A Bradley1

  • 1Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.

Insights

Histone deacetylase (HDAC) inhibitors can overcome resistance to radiotherapy in non-small cell lung cancer (NSCLC) by downregulating FLIP, a protein that inhibits cancer cell death. This strategy enhances cancer cell death and improves response to radiotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Resistance to radiotherapy in non-small cell lung cancer (NSCLC) is often due to insufficient cancer cell death.
  • FLIP, an endogenous caspase-8 inhibitor, is frequently overexpressed in NSCLC and inhibits apoptosis via the extrinsic death receptor pathway.

Purpose of the Study:

  • To investigate the role of the extrinsic apoptosis pathway and FLIP in radioresistance in NSCLC.
  • To evaluate the potential of histone deacetylase (HDAC) inhibitors to radiosensitize NSCLC by targeting FLIP.

Main Methods:

  • RNA interference (RNAi) was used to deplete caspase-8 and FLIP in NSCLC cells.
  • Overexpression of wild-type and mutant FLIP was employed to assess its role in radiation-induced apoptosis.
  • NSCLC cell lines were treated with HDAC inhibitors (vorinostat, entinostat) in combination with ionizing radiation (IR).
  • Antitumor activity of entinostat and IR was evaluated in vivo.

Main Results:

  • Ionizing radiation (IR)-induced apoptosis in NSCLC cells was dependent on caspase-8, indicating extrinsic pathway involvement.
  • Overexpression of FLIP attenuated IR-induced apoptosis, while FLIP downregulation enhanced IR-induced cell death.
  • HDAC inhibitors vorinostat and entinostat sensitized a subset of NSCLC cell lines to IR by suppressing FLIP and activating caspase-8.
  • Entinostat demonstrated enhanced antitumor activity when combined with IR in vivo.

Conclusions:

  • The extrinsic apoptosis pathway, regulated by FLIP, plays a critical role in determining NSCLC response to radiotherapy.
  • Pharmacological downregulation of FLIP using HDAC inhibitors represents a promising strategy to overcome radioresistance in NSCLC.
  • HDAC inhibitors may improve radiotherapy outcomes for NSCLC patients by enhancing cancer cell death.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63